The EUTOS prognostic score: review and validation in 1288 patients with CML treated frontline with imatinib.
about
Role of tyrosine-kinase inhibitors in myeloproliferative neoplasms: comparative lessons learnedChronic myeloid leukemia: reminiscences and dreamsLeukostasis in Children and Adolescents with Chronic Myeloid Leukemia: Japanese Pediatric Leukemia/Lymphoma Study Group.Changing Treatment May Affect the Predictive Ability of European Treatment Outcome Study Scoring for the Prognosis of Patients with Chronic Myeloid Leukemia.European Treatment and Outcome Study score does not predict imatinib treatment response and outcome in chronic myeloid leukemia patientsComparison of the utility and applicability of the Sokal, Hasford, and EUTOS scores in a population of Chinese patients with chronic-phase chronic myeloid leukemia undergoing imatinib therapyAccelerated phase chronic myeloid leukemia: evaluation of clinical criteria as predictors of survival, major cytogenetic response and progression to blast phase.The Hasford Score May Predict Molecular Response in Chronic Myeloid Leukemia Patients: A Single Institution ExperiencePrognostic and predictive implications of Sokal, Euro and EUTOS scores in chronic myeloid leukaemia in the imatinib era-experience from a tertiary oncology centre in Southern India.Consistency Test between Scoring Systems for Predicting Outcomes of Chronic Myeloid Leukemia in a Saudi Population Treated with Imatinib.Potential mechanisms of disease progression and management of advanced-phase chronic myeloid leukemia.Impact of risk score calculations in choosing front-line tyrosine kinase inhibitors for patients with newly diagnosed chronic myeloid leukemia in the chronic phase.Prognostic scores for patients with chronic myeloid leukemia under particular consideration of competing causes of death.Introduction of second-generation tyrosine kinase inhibitors may reduce the prognostic impact of high-risk patients, according to the European treatment and outcome study (EUTOS) score.Considering baseline factors and early response rates to optimize therapy for chronic myeloid leukemia in chronic phase.Accelerated Phase CML: Outcomes in Newly Diagnosed vs. Progression From Chronic Phase.Treatment and outcome of 2904 CML patients from the EUTOS population-based registry.Insights into the management of chronic myeloid leukemia in resource-poor settings: a Mexican perspective.Long-term outcome of chronic myeloid leukemia patients treated frontline with imatinib.Can prognostic scoring systems for chronic myeloid leukemia as established in adults be applied to pediatric patients?The EUTOS population-based registry: incidence and clinical characteristics of 2904 CML patients in 20 European Countries.Prognosis of long-term survival considering disease-specific death in patients with chronic myeloid leukemia.Intelligent Techniques Using Molecular Data Analysis in Leukaemia: An Opportunity for Personalized Medicine Support System.Moderate anemia at diagnosis is an independent prognostic marker of the EUTOS, Sokal, and Hasford scores for survival and treatment response in chronic-phase, chronic myeloid leukemia patients with frontline imatinib.The impact of early molecular response in children and adolescents with chronic myeloid leukemia treated with imatinib: a single-center study from China.Diagnostic and prognostic cytogenetics of chronic myeloid leukaemia: an update.Defining therapy goals for major molecular remission in chronic myeloid leukemia: results of the randomized CML Study IV.Performance of Sokal and Eutos Scores for Predicting Cytogenetic and Molecular Response in Newly Diagnosed Chronic Myeloid Leukemia-Chronic Phase Patients on Imatinib.The European Treatment and Outcome Study score is associated with clinical outcomes and treatment response following European LeukemiaNet 2013 recommendations in chronic-phase chronic myeloid leukemia.Prognostic discrimination for early chronic phase chronic myeloid leukemia in imatinib era: comparison of Sokal, Euro, and EUTOS scores in Korean population.
P2860
Q26738514-A68E3305-03C4-49ED-A31B-871E1F9E7CB9Q26748769-BB9BE8CC-9FB9-4787-8A1B-D686AF356038Q33166364-04F03210-987E-4253-8212-7F7EDB22410AQ33747763-D7800839-15E7-437A-A326-4386ACB62AFFQ35051720-DAC00A50-01BE-4814-B344-0205923C9FDFQ36068354-E32B49C4-6924-406C-AF08-0DAD85F6C82CQ36387433-BDE089E9-83B6-4455-8FA6-FD87B05D59B9Q37366701-21D98B59-EC27-4D42-A2B7-B9D216B6A0A7Q37404680-3DBE7B95-F156-409E-9E99-6F2D6BA2C8FBQ37668884-57A2A81F-5ECD-4563-888E-0B8DD1DF7C8BQ38139571-E95D51B5-7DC7-48FB-97F9-C2467CA8DD79Q38207114-C3CF044A-4190-4CDE-B3BA-319DCEF63CABQ38392698-4E5075E3-8359-4295-A4E7-F6E789D4E0C5Q38609730-3C6493E9-52DC-4E61-B4D6-68FACFBE316DQ38685803-187D3D02-94FB-4827-A416-E5B9D60A6B61Q38757051-7109938C-16CB-4DF8-8312-8032C16F9C46Q39446340-A632BA47-AE9C-4FAB-8B22-4470BB99D5FEQ39457369-62A3FCCD-421F-4A71-B220-A920D95A7A8EQ40821920-4F7EA553-25B8-4597-8CB1-9F1DF3F083CFQ41038941-04DC9FDC-42D7-4751-B574-7FF89741B824Q41200962-6693C540-66D1-49CA-86C1-9588FBD81476Q41293762-D6045026-AE8F-49D5-A922-2F115AA91EB2Q41294047-93FAE869-D093-443D-8DF0-A4DC7B316128Q47824125-23F01BE3-8724-4230-9B83-2CB92521C13BQ48243531-5E4592FA-993A-4D52-AFA0-6238A758C9B8Q49993294-C68EB27A-0544-4D9A-982C-A8E139F040CEQ50421953-9D6B2D69-5227-4183-88DF-275CBB69F4DBQ53508619-99452648-E389-4DA1-AB90-42D4F3735E8DQ54332885-E34706B3-AD83-4956-AB17-07A2C19A0EE8Q54348857-0B25C698-88A0-4049-B532-A677CB93685C
P2860
The EUTOS prognostic score: review and validation in 1288 patients with CML treated frontline with imatinib.
description
article científic
@ca
article scientifique
@fr
articol științific
@ro
articolo scientifico
@it
artigo científico
@gl
artigo científico
@pt
artigo científico
@pt-br
artikel ilmiah
@id
artikull shkencor
@sq
artículo científico
@es
name
The EUTOS prognostic score: re ...... eated frontline with imatinib.
@en
type
label
The EUTOS prognostic score: re ...... eated frontline with imatinib.
@en
prefLabel
The EUTOS prognostic score: re ...... eated frontline with imatinib.
@en
P2093
P2860
P356
P1433
P1476
The EUTOS prognostic score: re ...... reated frontline with imatinib
@en
P2093
A Hellmann
A Zaritsky
D Lindoerfer
F Castagnetti
J-L Steegmann
M Baccarani
P2860
P2888
P304
P356
10.1038/LEU.2013.171
P50
P577
2013-06-11T00:00:00Z
P6179
1039255559